Belenos’ Keymed licensing deal delivers on Phase II win in rhinosinusitis
Belenos Biosciences’ bet worth up to $185m on Keymed Biosciences’ subcutaneous chronic rhinosinusitis with nasal polyps (CRSwNP) therapy is showing …
Post
-
-
Why your manufacturing floor is your greatest compliance risk – and opportunity
Ask any life sciences quality leader where their biggest compliance headaches originate, and you might expect them to point to …
-
Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli
A patient who developed multidrug-resistant E. coli following a transplant has recovered following treatment with an investigational clustered regularly interspaced …
-
Arch Biopartners plans US expansion of LSALT peptide trial
Arch Biopartners is set to expand its Phase II clinical trial of the LSALT peptide, a drug candidate targeting cardiac …
-
First patient in Skylark Bio’s Phase I/II trial receives SKY-GJB2 gene therapy
Skylark Bio has dosed the first patient in its SONIX Phase I/II clinical trial assessing SKY-GJB2 as a potential gene …
-
MoonLake’s nanobody boosts PsA indication hopes after Phase III success
MoonLake Immunotherapeutics’ sonelokimab has shown benefit in patients with psoriatic arthritis (PsA), with a Phase III trial meeting its primary …
-
Commercialising drugs in Europe: Lean models for first-time launchers
In 2025, 193 innovative drugs received approval in Europe, including 133 new molecular entities (NMEs). Over half – 56% - …
-
Silence’s stock soars on divesiran’s Phase II polycythaemia vera success
British biotech Silence Therapeutics has been making noise on the stock markets by posting 30% growth in its share price …
-
Tenax Therapeutics’ stock crashes on Phase III trial failure
Tenax Therapeutics’ stock dropped by nearly 90% after a Phase III trial of its oral therapy for pulmonary hypertension associated …
-
First patient dosed in Artelo’s Phase II DREAM study for glaucoma
Artelo Biosciences has dosed the first patient in the Phase II DREAM study assessing ART27.13 as a potential treatment for …
-
Clinical trial success increasingly dependent on strategic collaborations and tech applications
As clinical trials become more expensive to run, well-rationalised collaboration and budgetary planning dictates are crucial, while unlocking valuable data …
-
AbCellera reports favourable Phase II data for ABCL635
AbCellera has reported encouraging top-line data from the Phase II segment of its Phase I/II study assessing ABCL635, an investigational …
-
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market
The FDA has approved Moderna’s messenger RNA (mRNA) seasonal influenza vaccine, mFLUSIVA (mRNA-1010), for the prevention of seasonal influenza in …
-
Soligenix culls topical lymphoma asset after Phase III miss
Soligenix has terminated the late-stage development programme for its topical cutaneous T-cell lymphoma (CTCL) therapy, HyBryte, after the drug failed …
-
WHO calls for Phase III Ervebo vaccine trial amid Bundibugyo Ebola outbreak
A panel held by the World Health Organization (WHO) has called for a Phase III trial of the Zaire Ebolavirus …
